Two medicines, side by side
Budesonide vs ipratropium
Budesonide and ipratropium are both labeled for allergies. Drugs@FDA records approvals of budesonide since 1994 and of ipratropium since 1986. Pharmacies paid $0.498 per budesonide DR 3 mg capsule and $0.111 per mL (Ipratropium br 0.02% solution) (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. Budesonide's other strengths are brand-only: $3.29 per mL (Eohilia 2 mg/10 mL packet). In FDA's classes, budesonide is a corticosteroid and ipratropium an anticholinergic.
Check it at the source: the budesonide FDA label on DailyMed (effective October 11, 2019); the ipratropium FDA label on DailyMed (effective January 8, 2026).
Highlights of the budesonide record
Budesonide (Pulmicort) · label of October 11, 2019
Used for
From the label: indicationsPULMICORT RESPULES ® is an inhaled corticosteroid indicated for: • Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Maintenance Treatment of Asthma PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. […]
On the market
- Earliest approval on file
- February 14, 1994
- Generic labelers
- 30 labelers
- Pharmacy cost
- $0.498 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 9
Highlights of the ipratropium record
Ipratropium (Atrovent) · label of January 8, 2026
Used for
From the label: indicationsIpratropium bromide nasal solution, 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis.
On the market
- Earliest approval on file
- December 29, 1986
- Generic labelers
- 23 labelers
- Pharmacy cost
- $0.111 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Source: FDA drug labels via openFDA (Budesonide label of October 11, 2019, Ipratropium label of January 8, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do budesonide and ipratropium differ on the record?
In FDA's classes, budesonide is a corticosteroid and ipratropium an anticholinergic.
Generics: budesonide since 2008; ipratropium since 1997 (Drugs@FDA).
| Budesonide | Ipratropium | |
|---|---|---|
| Labeled for | Asthma, Allergies, Crohn's disease and ulcerative colitis | COPD, Allergies, Cough and cold |
| Pharmacologic class | Corticosteroid | Anticholinergic |
| How it works (label) | Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. | n/a |
| Half-life (label) | n/a | Elimination After intravenous administration of 2 mg ipratropium bromide to 10 healthy volunteers, the terminal half-life of ipratropium was approximately 1.6 hours. |
| Earliest approval on file (Drugs@FDA) | February 14, 1994 | December 29, 1986 |
| First generic approved | November 18, 2008 | January 10, 1997 |
| Generic labelers (NDC) | 30 labelers | 23 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.498 per capsule (Budesonide DR 3 mg capsule) | $0.111 per mL (Ipratropium br 0.02% solution) |
| 12-month price change | -3% | +11% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 9 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 58,575 | 35,481 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to budesonide
- every medicine labeled for the same conditions